Michael Shalmi

Managing Director, Principal Investments at Novo Holding A/S

Michael Shalmi

Michael Shalmi

Managing Director, Principal Investments at Novo Holding A/S

Overview
RelSci Relationships

329

Number of Boards

6

Birthday

1965

Age

54

Relationships
RelSci Relationships are individuals Michael Shalmi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Advisor at VF Venture

Relationship likelihood: Strong

Co-Founder at Aerocrine AB

Relationship likelihood: Strong

Chief Executive Officer & Director at Momentum Gruppen A/S

Relationship likelihood: Strong

Former Chief Financial Officer at Novo Holding A/S

Relationship likelihood: Strong

Founding Partner at HealthCap AB

Relationship likelihood: Strong

Partner at Cinven Partners LLP

Relationship likelihood: Strong

Former Director at Synlab International GmbH

Relationship likelihood: Strong

Partner at Cinven Group Ltd.

Relationship likelihood: Strong

Partner at Cinven Group Ltd.

Relationship likelihood: Strong

Asset Director Large Investments at Novo Holding A/S

Relationship likelihood: Strong

Paths to Michael Shalmi
Potential Connections via
Relationship Science
You
Michael Shalmi
Managing Director, Principal Investments at Novo Holding A/S
Education
MD Medicine

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark. The purpose of the University – to quote the University Statute – is to ’conduct research and provide further education to the highest academic level’.

Watching SIMI - Scandinavian International Management Institute.

Career History
Managing Director
2009 - Current

Novo Principal is an active manager which provides funding for growth-stage capital requirements, and makes co-investments. The firm invests in both public and private companies from Northern Europe and North America. Novo Principal targets companies operating in the health technology and health services sector, and industries such as biotechnology and medical specialties. It looks to take both minority and majority stake positions in its investments, as well as a seat on the board.

Managing Director, Principal Investments
Current

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation's assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Chief Medical Officer, BioPharm
2008 - 2009

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Boards & Committees
Member-Supervisory Board
2017 - Current

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Director
2017 - Current

SYNLAB Ltd. provides clinical laboratory services, drug and alcohol testing, food testing, oil and fuel analysis and veterinary testing. The company was founded on June 9, 2015 and is headquartered in London, the United Kingdom.

Director
2014 - Current

Aerocrine AB engages in the sale of medical technology products that are used to facilitate the diagnosis and improve the treatment and monitoring of patients with airway inflammation. It offers NIOX Flex and NIOX MINO, which are tools to assist in the diagnosis and control of airways disease. The company operates through the North America or USA and EU or the Rest of the World segments. Aerocrine was founded by Lars Gustafsson, Jon Lundberg and Eddie Weitzberg in November 1997 and is headquartered in Solna, Sweden.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael Shalmi. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael Shalmi's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael Shalmi.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/michael-shalmi-4411294
  • https://relationshipscience.com/person/michael-shalmi-4411294